financetom
Business
financetom
/
Business
/
F5 Holds History of Adding to Earnings-Driven After-Hours Gains in Next Day's Regular Session
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
F5 Holds History of Adding to Earnings-Driven After-Hours Gains in Next Day's Regular Session
Apr 29, 2024 3:37 AM

06:04 AM EDT, 04/29/2024 (MT Newswires) -- F5 (FFIV) has historically offered longs a better trading opportunity in its post-earnings after-hours and regular session trade.

FFIV has seen an after-hours earnings-driven gain in 43 of the 79 quarters we've tracked in our database over the last 20 years and 26 times recorded a more aggressive upside move in next-day regular session trade, or 60% of the time.

The stock has declined in 36 after-hours moves, and added to that downside 16 times in next-day action, or 44% of the time - and reversing or narrowing its downside 56% of the time.

FFIV is due with its Q2 results in the after-hours session today, and analysts polled by Capital IQ expect the company to post a profit of $2.87 per share on revenue of $684 million.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Medtronic Receives CE Mark Approval for Parkinson's Disease Therapy Device in EU, UK
Medtronic Receives CE Mark Approval for Parkinson's Disease Therapy Device in EU, UK
Jan 13, 2025
04:23 AM EST, 01/13/2025 (MT Newswires) -- Medtronic ( MDT ) said Monday it received CE Mark approval for its BrainSense Adaptive Deep Brain Stimulation and BrainSense Electrode Identifier, a Parkinson's disease therapy device, in the European Union and the UK. The company said the approval confirms that the devices meet the EU medical device regulation standards. ...
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment
Teva Pharmaceuticals International Enters Collaboration to Commercialize Eye Disease Treatment
Jan 13, 2025
04:32 AM EST, 01/13/2025 (MT Newswires) -- Teva Pharmaceutical Industries' ( TEVA ) Teva Pharmaceuticals International subsidiary said Monday it has entered into a collaboration with Klinge Biopharma and Formycon for the semi-exclusive commercialization of FYB203, Formycon's biosimilar candidate to Eylea, in Israel and Europe, excluding Italy. Financial terms were not disclosed. Klinge has licensed the exclusive global commercialization rights...
Amicus Therapeutics Reports Preliminary Q4 Revenue
Amicus Therapeutics Reports Preliminary Q4 Revenue
Jan 13, 2025
04:15 AM EST, 01/13/2025 (MT Newswires) -- Amicus Therapeutics ( FOLD ) on Sunday reported preliminary Q4 revenue of $149.9 million. Analysts polled by FactSet expect $147.5 million. For full-year 2025, the company expects revenue to grow between 17% and 24% at a constant exchange rate. The company also projects positive net income for the second half of 2025. ...
W&T Offshore to Offer $350 Million of Senior Notes
W&T Offshore to Offer $350 Million of Senior Notes
Jan 13, 2025
04:24 AM EST, 01/13/2025 (MT Newswires) -- W&T Offshore ( WTI ) said Monday that it plans to offer $350 million of senior second lien notes due 2029 in a private offering. The company said it plans to use the net proceeds, along with cash on hand, primarily to buy its outstanding 11.75% senior second lien notes due 2026 and...
Copyright 2023-2026 - www.financetom.com All Rights Reserved